AU2012321106C1 - Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent - Google Patents

Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent Download PDF

Info

Publication number
AU2012321106C1
AU2012321106C1 AU2012321106A AU2012321106A AU2012321106C1 AU 2012321106 C1 AU2012321106 C1 AU 2012321106C1 AU 2012321106 A AU2012321106 A AU 2012321106A AU 2012321106 A AU2012321106 A AU 2012321106A AU 2012321106 C1 AU2012321106 C1 AU 2012321106C1
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
administered
cancer
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012321106A
Other languages
English (en)
Other versions
AU2012321106B2 (en
AU2012321106A1 (en
Inventor
Peter G. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2012321106A1 publication Critical patent/AU2012321106A1/en
Publication of AU2012321106B2 publication Critical patent/AU2012321106B2/en
Application granted granted Critical
Publication of AU2012321106C1 publication Critical patent/AU2012321106C1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: MILLENNIUM PHARMACEUTICALS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012321106A 2011-11-03 2012-11-02 Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent Ceased AU2012321106C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555049P 2011-11-03 2011-11-03
US61/555,049 2011-11-03
PCT/US2012/063382 WO2013067396A2 (en) 2011-11-03 2012-11-02 Administration of nedd8-activating enzyme inhibitor and hypomethylating agent

Publications (3)

Publication Number Publication Date
AU2012321106A1 AU2012321106A1 (en) 2013-05-23
AU2012321106B2 AU2012321106B2 (en) 2016-08-04
AU2012321106C1 true AU2012321106C1 (en) 2016-11-24

Family

ID=48193039

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012321106A Ceased AU2012321106C1 (en) 2011-11-03 2012-11-02 Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent

Country Status (23)

Country Link
US (2) US8980850B2 (cg-RX-API-DMAC10.html)
EP (1) EP2773360B1 (cg-RX-API-DMAC10.html)
JP (2) JP6231988B2 (cg-RX-API-DMAC10.html)
KR (1) KR101987861B1 (cg-RX-API-DMAC10.html)
CN (1) CN104245699B (cg-RX-API-DMAC10.html)
AU (1) AU2012321106C1 (cg-RX-API-DMAC10.html)
BR (1) BR112014010699B1 (cg-RX-API-DMAC10.html)
CA (1) CA2854461C (cg-RX-API-DMAC10.html)
EA (1) EA028380B1 (cg-RX-API-DMAC10.html)
ES (1) ES2668272T3 (cg-RX-API-DMAC10.html)
GE (2) GEP20196940B (cg-RX-API-DMAC10.html)
HK (1) HK1201733A1 (cg-RX-API-DMAC10.html)
IL (1) IL232353B (cg-RX-API-DMAC10.html)
MA (1) MA35662B1 (cg-RX-API-DMAC10.html)
MX (1) MX357835B (cg-RX-API-DMAC10.html)
MY (1) MY176125A (cg-RX-API-DMAC10.html)
PH (1) PH12014501001B1 (cg-RX-API-DMAC10.html)
PL (1) PL2773360T3 (cg-RX-API-DMAC10.html)
SG (1) SG11201401895WA (cg-RX-API-DMAC10.html)
TN (1) TN2014000194A1 (cg-RX-API-DMAC10.html)
TR (1) TR201807342T4 (cg-RX-API-DMAC10.html)
UA (1) UA114414C2 (cg-RX-API-DMAC10.html)
WO (1) WO2013067396A2 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2430026A1 (en) 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
MY166889A (en) * 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
EP2764866A1 (en) * 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
CN105407973A (zh) 2013-05-14 2016-03-16 米伦纽姆医药公司 Nedd8活化酶抑制剂及化学治疗剂的投与
EA201600134A1 (ru) * 2013-07-26 2016-07-29 Бёрингер Ингельхайм Интернациональ Гмбх Воласертиб в комбинации с азацитидином для лечения острого миелоидного лейкоза и миелодиспластического синдрома
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
CA3002029A1 (en) * 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
US11701406B2 (en) 2017-05-25 2023-07-18 The Board Of Trustees Of The Leland Stanford Junior University Combination of low dose IL-2 and an inhibitor of Treg IL-2R desensitization to treat autoimmune and allergic inflammatory diseases
JP2020534331A (ja) * 2017-09-21 2020-11-26 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. ((1s,2s,4r)−4−{4−[(1s)−2,3−ジヒドロ−1h−インデン−1−イルアミノ]−7h−ピロロ[2,3−d]ピリミジン−7−イル}−2−ヒドロキシシクロペンチル)メチルスルファメートの共結晶形態、その製剤及び使用
CA3119781A1 (en) * 2018-11-20 2020-05-28 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease
IL323757A (en) 2019-03-15 2025-12-01 Fulcrum Therapeutics Inc Macrocyclic azolopyridine derivatives as eed and prc2 modulators
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy
WO2023242235A1 (en) * 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
CN115007323B (zh) * 2022-06-17 2024-01-23 中南大学 一种抑制矿物中黄铁矿浮选的方法
US20260023068A1 (en) * 2022-07-11 2026-01-22 Westlake University Use of a fbxo42 specific inhibitor in treating notch signaling-dependent disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
WO2006084281A1 (en) 2005-02-04 2006-08-10 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
HRP20120786T1 (hr) 2006-02-02 2012-11-30 Millennium Pharmaceuticals, Inc. Inhibitori aktivirajuä†eg enzima e1
ME02789B (me) * 2006-08-08 2011-06-30 Millennium Pharm Inc Jedinjenja heteroarila korisna kao inhibitori e1 aktivirajućih enzima
WO2008028193A2 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
US20100311683A1 (en) 2007-11-01 2010-12-09 Beach C L Cytidine analogs for treatment of myelodysplastic syndromes
US20110021517A1 (en) * 2008-02-26 2011-01-27 Nerviano Medical Sciences S.R.L. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
PL2307002T3 (pl) * 2008-06-09 2013-05-31 Cyclacel Ltd Kombinacje sapacytabiny lub cndac z inhibitorami metylotransferazy dna, takimi jak decytabina i prokaina
CN102438588B (zh) * 2009-03-23 2015-04-01 埃姆比特生物科学公司 使用联合治疗法治疗疾病的方法
EP2430026A1 (en) 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
JP6162709B2 (ja) 2011-11-01 2017-07-12 セルジーン コーポレイション シチジンアナログの経口製剤を使用して癌を治療する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG M. et al, Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer, Expert Opin. Ther. Targets (2011) 15(3):253-264 *

Also Published As

Publication number Publication date
MX357835B (es) 2018-07-26
EA028380B1 (ru) 2017-11-30
NZ624881A (en) 2016-10-28
AU2012321106B2 (en) 2016-08-04
US20130116208A1 (en) 2013-05-09
KR20140097229A (ko) 2014-08-06
WO2013067396A2 (en) 2013-05-10
EA201400539A1 (ru) 2014-12-30
MX2014005323A (es) 2014-06-05
PH12014501001B1 (en) 2018-05-04
ES2668272T3 (es) 2018-05-17
UA114414C2 (uk) 2017-06-12
TR201807342T4 (tr) 2018-06-21
EP2773360A2 (en) 2014-09-10
CN104245699B (zh) 2017-06-27
US20150366886A1 (en) 2015-12-24
PL2773360T3 (pl) 2018-09-28
JP2015505816A (ja) 2015-02-26
TN2014000194A1 (en) 2015-09-30
US8980850B2 (en) 2015-03-17
EP2773360A4 (en) 2015-09-23
WO2013067396A3 (en) 2014-10-16
CA2854461C (en) 2021-01-19
IL232353B (en) 2018-11-29
HK1201733A1 (en) 2015-09-11
BR112014010699A2 (pt) 2017-04-25
CN104245699A (zh) 2014-12-24
AU2012321106A1 (en) 2013-05-23
GEP20186940B (en) 2019-01-10
CA2854461A1 (en) 2013-05-10
EP2773360B1 (en) 2018-02-28
MY176125A (en) 2020-07-24
GEAP201813483A (en) 2018-09-10
BR112014010699B1 (pt) 2020-12-15
IL232353A0 (en) 2014-06-30
MA35662B1 (fr) 2014-11-01
JP2018009035A (ja) 2018-01-18
PH12014501001A1 (en) 2014-06-09
SG11201401895WA (en) 2014-05-29
GEP20196940B (en) 2019-01-10
KR101987861B1 (ko) 2019-06-11
JP6231988B2 (ja) 2017-11-15

Similar Documents

Publication Publication Date Title
AU2012321106B2 (en) Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent
JP5046922B2 (ja) 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物
Hong et al. Pharmacokinetic modeling optimizes inhibition of the ‘undruggable’EWS-FLI1 transcription factor in Ewing Sarcoma
KR20110028651A (ko) (a) 포스포이노시타이드 3-키나제 억제제 및 (b) ras/raf/mek 경로의 조절제의 조합물
AU2015314753A1 (en) Human dosing of phosphatase inhibitor
JP2016528217A (ja) 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
KR101760657B1 (ko) 약제학적 병용물
CN112165945A (zh) 治疗淋巴样恶性疾病之方法
US20140249167A1 (en) Administration of NEDD8-Activating Enzyme Inhibitor
US10786505B2 (en) Administration of NEDD8-activating enzyme inhibitor and chemotherapeutic agents
JP2021063014A (ja) 白血病治療薬
US20250064824A1 (en) Administration of aurora kinase inhibitor and chemotherapeutic agents
Dy et al. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors
AU2023228543B2 (en) Pharmaceutical combinations for use in the treatment of neoplastic diseases.
HK40110657A (en) Cdk4 inhibitor for the treatment of cancer
HK40069821A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
CA3141072A1 (en) Methods and uses for treating cancer

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 AUG 2016 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 AUG 2016

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): MILLENNIUM PHARMACEUTICALS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired